Moberg Pharma: A setback for the US study - Redeye

Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.

Länk till analysen i sin helhet: https://www.redeye.se/research/1039653/moberg-pharma-a-setback-for-the-us-study?utm_source=finwire&utm_medium=RSS